Cost and profitability Recent news indicates Certara faces higher costs and a quarterly net loss, highlighting a potential need for cost optimization, efficiency improvements, and scalable regulatory operations to protect margins.

AI and automation Certara is pursuing agentic AI workflows and an open integrated AI platform, presenting a sales opportunity for AI-assisted regulatory strategy, data analytics, and automated documentation to accelerate approvals.

Regulatory expansion With a global footprint across North America, Europe, and Asia Pacific, there is potential to expand regulatory strategy, medical writing, and publications services into new markets or underrepresented regions.

Strategic alignment Recent partnership with NVIDIA and Python API launch indicate a push toward integrated tech stacks; there is opportunity to offer end-to-end tech-enabled solutions that align with their platform strategy.

Asset divestiture signal Plans to sell Regulatory and Medical Writing assets suggest a shift in focus or restructuring; target opportunities may include acquiring or augmenting remaining core capabilities through managed services or integration partnerships.